Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response.

ABSTRACT: Major depressive disorder is highly prevalent worldwide and has been affecting an increasing number of people each year. Current first line antidepressants show merely 37% remission, and physicians are forced to use a trial-and-error approach when choosing a single antidepressant out of dozens of available medications. We sought to identify a method of testing that would provide patient-specific information on whether a patient will respond to a medication using in vitro modeling. Patient-derived lymphoblastoid cell lines from the Sequenced Treatment Alternatives to Relieve Depression study were used to rapidly generate cortical neurons and screen them for bupropion effects, for which the donor patients showed remission or non-remission. We provide evidence for biomarkers specific for bupr

SUBMITTER: Avior Y 

PROVIDER: S-EPMC8016835 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature